M2 Pharma - Therapy Areas

Eli Lilly signs definitive agreement to acquire Orna Therapeutics

10 February 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that it has signed a definitive agreement to acquire Orna Therapeutics Inc, a biotechnology company fo...

Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia

9 February 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that the US Food and Drug Administration (FDA) has granted breakthrough therapy designatio...

AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV

4 February 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) ...

WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals

3 February 2026 - WuXi Biologics (HKG:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Monday that it has entered into a licence and res...

I Peace generates human iPS cells from NKT cells and offers them for research use

2 February 2026 - I Peace Inc, a California-based GMP cell therapy CDMO, announced on Friday that it has generated human induced pluripotent stem (iPS) cells from NKT cells and has started offering th...

Repertoire Immune Medicines teams up with Eli Lilly and Company to develop tolerizing therapies for autoimmune diseases

30 January 2026 - Biotechnology company Repertoire Immune Medicines announced on Thursday that it has entered into a strategic collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY...